Annual Report 2022

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2022 126 The United Laboratories International Holdings Limited Annual Report 2022 31. SHARE CAPITAL (Continued) Notes: (i) During the year ended 31 December 2022, the Company repurchased its own ordinary shares through the Stock Exchange as follows: Month of repurchase No. of ordinary shares of HK$0.01 each Price per share Aggregate consideration paid Highest Lowest HK$ HK$ HK$’000 January 3,324,000 4.60 4.38 14,744 March 3,068,000 4.10 3.95 12,274 April 5,524,000 4.10 4.00 22,618 September 4,000 3.20 3.20 13 October 544,000 3.20 3.17 1,736 RMB’000 Shown in the consolidated financial statements as: At 31 December 2022 42,044 (ii) During the year ended 31 December 2021, the Company repurchased its own ordinary shares through the Stock Exchange as follows: Month of repurchase No. of ordinary shares of HK$0.01 each Price per share Aggregate consideration paid Highest Lowest HK$ HK$ HK$’000 December 10,900,000 4.60 4.46 49,869 RMB’000 Shown in the consolidated financial statements as: At 31 December 2021 40,978 6,184,000 ordinary shares were cancelled upon repurchase and the remaining 4,716,000 ordinary shares have not yet been cancelled as at 31 December 2021 and therefore classified as treasury stocks. All the treasury stocks have been cancelled as at 31 December 2022. None of the Company’s subsidiaries purchased, sold or redeemed any of the Company’s listed securities during the year.